Forward Pharma A/S was a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The company completed a voluntary solvent liquidation in 2025.
Looking for a particular Forward Pharma A/S employee's phone or email?
Forward Pharma A/S Questions
The Forward Pharma A/S annual revenue was $644000 in 2026.
6 people are employed at Forward Pharma A/S.
Forward Pharma A/S is based in København K, Capital Region.
The NAICS codes for Forward Pharma A/S are [32541, 32, 3254, 325].
The SIC codes for Forward Pharma A/S are [283, 28].
Top Forward Pharma A/S Employees
Related Companies
